Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$109.04 USD

109.04
690,717

-2.37 (-2.13%)

Updated Oct 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Jazz (JAZZ) Down 7.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Jazz Pharmaceuticals (JAZZ) a Profitable Value Stock?

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) stock may be a good choice for value-oriented investors right now from multiple angles.

Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

by Zacks Equity Research

Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.

Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.

Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

by Zacks Equity Research

Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.

Sanghamitra Saha headshot

ETF & Stock Winners of Longest US Economic Expansion

by Sanghamitra Saha

The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.

JAZZ or PCRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. PCRX: Which Stock Is the Better Value Option?

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

by Zacks Equity Research

Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

by Zacks Equity Research

Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

Is Jazz (JAZZ) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Urmimala Biswas headshot

5 Best PEG Stocks Suitable for GARP Investors

by Urmimala Biswas

While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.

BioCryst Down Despite Hereditary Angioedema Study Meets Goal

by Zacks Equity Research

BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.

JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

JAZZ vs. PCRX: Which Stock Is the Better Value Option?

Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates

by Zacks Equity Research

So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.

3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)

by Zacks Equity Research

Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.